Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis

Chris L. Ayers, Jason P. Mendoza, Sushmita Sinha, Khrishen Cunnusamy, Benjamin Greenberg, Elliot Frohman, Nitin J. Karandikar

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Daily administration of FDA-approved glatiramer acetate (GA) has beneficial effects on clinical course of relapsing remitting multiple sclerosis (RRMS). Although mechanisms of GA-action have been widely investigated and partially understood, immediate immune dynamics following GA-therapy are unknown. In the present study, we characterized the immediate effects of GA on phenotype, quantity and function of immune cells in MS patients. Prominent changes in immune cells were detected within 4-12. h post-first GA-injection. T-cell modulation included significantly decreased CD4/CD8 ratio, perturbed homeostasis of predominantly CD8. + T-cells, significant enhancement in CD8. + T-cell mediated suppression and inhibitory potential of induced CD4-suppressors. Changes in APC were restricted to monocytes and included reduced stimulatory capacity in MLR and significantly increased IL-10 and TNF-α production. Our study provides the first evidence that GA treatment induces rapid immunologic changes within hours of first dose. Interestingly, these responses are not only restricted to innate immune cells but also include complex modulation of T-cell functionality.

Original languageEnglish (US)
Pages (from-to)105-119
Number of pages15
JournalClinical Immunology
Volume147
Issue number2
DOIs
StatePublished - May 2013

Fingerprint

Multiple Sclerosis
T-Lymphocytes
Therapeutics
Relapsing-Remitting Multiple Sclerosis
CD4-CD8 Ratio
Interleukin-10
Glatiramer Acetate
Monocytes
Homeostasis
Phenotype
Injections

Keywords

  • Glatiramer acetate
  • Immunomodulation
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. / Ayers, Chris L.; Mendoza, Jason P.; Sinha, Sushmita; Cunnusamy, Khrishen; Greenberg, Benjamin; Frohman, Elliot; Karandikar, Nitin J.

In: Clinical Immunology, Vol. 147, No. 2, 05.2013, p. 105-119.

Research output: Contribution to journalArticle

Ayers, Chris L. ; Mendoza, Jason P. ; Sinha, Sushmita ; Cunnusamy, Khrishen ; Greenberg, Benjamin ; Frohman, Elliot ; Karandikar, Nitin J. / Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. In: Clinical Immunology. 2013 ; Vol. 147, No. 2. pp. 105-119.
@article{48b3b30b76fe4487bbe096f54761e19e,
title = "Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis",
abstract = "Daily administration of FDA-approved glatiramer acetate (GA) has beneficial effects on clinical course of relapsing remitting multiple sclerosis (RRMS). Although mechanisms of GA-action have been widely investigated and partially understood, immediate immune dynamics following GA-therapy are unknown. In the present study, we characterized the immediate effects of GA on phenotype, quantity and function of immune cells in MS patients. Prominent changes in immune cells were detected within 4-12. h post-first GA-injection. T-cell modulation included significantly decreased CD4/CD8 ratio, perturbed homeostasis of predominantly CD8. + T-cells, significant enhancement in CD8. + T-cell mediated suppression and inhibitory potential of induced CD4-suppressors. Changes in APC were restricted to monocytes and included reduced stimulatory capacity in MLR and significantly increased IL-10 and TNF-α production. Our study provides the first evidence that GA treatment induces rapid immunologic changes within hours of first dose. Interestingly, these responses are not only restricted to innate immune cells but also include complex modulation of T-cell functionality.",
keywords = "Glatiramer acetate, Immunomodulation, Multiple sclerosis",
author = "Ayers, {Chris L.} and Mendoza, {Jason P.} and Sushmita Sinha and Khrishen Cunnusamy and Benjamin Greenberg and Elliot Frohman and Karandikar, {Nitin J.}",
year = "2013",
month = "5",
doi = "10.1016/j.clim.2013.02.015",
language = "English (US)",
volume = "147",
pages = "105--119",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis

AU - Ayers, Chris L.

AU - Mendoza, Jason P.

AU - Sinha, Sushmita

AU - Cunnusamy, Khrishen

AU - Greenberg, Benjamin

AU - Frohman, Elliot

AU - Karandikar, Nitin J.

PY - 2013/5

Y1 - 2013/5

N2 - Daily administration of FDA-approved glatiramer acetate (GA) has beneficial effects on clinical course of relapsing remitting multiple sclerosis (RRMS). Although mechanisms of GA-action have been widely investigated and partially understood, immediate immune dynamics following GA-therapy are unknown. In the present study, we characterized the immediate effects of GA on phenotype, quantity and function of immune cells in MS patients. Prominent changes in immune cells were detected within 4-12. h post-first GA-injection. T-cell modulation included significantly decreased CD4/CD8 ratio, perturbed homeostasis of predominantly CD8. + T-cells, significant enhancement in CD8. + T-cell mediated suppression and inhibitory potential of induced CD4-suppressors. Changes in APC were restricted to monocytes and included reduced stimulatory capacity in MLR and significantly increased IL-10 and TNF-α production. Our study provides the first evidence that GA treatment induces rapid immunologic changes within hours of first dose. Interestingly, these responses are not only restricted to innate immune cells but also include complex modulation of T-cell functionality.

AB - Daily administration of FDA-approved glatiramer acetate (GA) has beneficial effects on clinical course of relapsing remitting multiple sclerosis (RRMS). Although mechanisms of GA-action have been widely investigated and partially understood, immediate immune dynamics following GA-therapy are unknown. In the present study, we characterized the immediate effects of GA on phenotype, quantity and function of immune cells in MS patients. Prominent changes in immune cells were detected within 4-12. h post-first GA-injection. T-cell modulation included significantly decreased CD4/CD8 ratio, perturbed homeostasis of predominantly CD8. + T-cells, significant enhancement in CD8. + T-cell mediated suppression and inhibitory potential of induced CD4-suppressors. Changes in APC were restricted to monocytes and included reduced stimulatory capacity in MLR and significantly increased IL-10 and TNF-α production. Our study provides the first evidence that GA treatment induces rapid immunologic changes within hours of first dose. Interestingly, these responses are not only restricted to innate immune cells but also include complex modulation of T-cell functionality.

KW - Glatiramer acetate

KW - Immunomodulation

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84876337179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876337179&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2013.02.015

DO - 10.1016/j.clim.2013.02.015

M3 - Article

C2 - 23578552

AN - SCOPUS:84876337179

VL - 147

SP - 105

EP - 119

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -